scholarly journals Erratum to: 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide

2015 ◽  
Vol 42 (8) ◽  
pp. 1337-1338 ◽  
Author(s):  
Ugo De Giorgi ◽  
Paola Caroli ◽  
Emanuela Scarpi ◽  
Vincenza Conteduca ◽  
Salvatore Luca Burgio ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Response Assessment ◽  
Early Response ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Pet Ct ◽  
Early Response Assessment

scholarly journals Exploratory Study of [18F]fluciclovine PET/CT for Response Assessment to Docetaxel in Patients with Metastatic Castration Resistant Prostate Cancer

2020 ◽  
Author(s):  
Akinyemi A Akintayo ◽  
Mehmet A Bilen ◽  
Olayinka A Abiodun-Ojo ◽  
Omer Kucuk ◽  
Bradley Carthon ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Scan ◽  
Progressive Disease ◽  
Specific Antigen ◽  
Response Assessment ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Pet Ct ◽  
Psa Response ◽  
Psa Progression

Abstract Background The ability to accurately monitor response to treatment in patients with metastatic castration resistant prostate cancer (mCRPC) on chemotherapy has been a challenge. Conventional methods of therapy response assessment have limitations and molecular imaging has been explored as an important alternative. We set out t o determine if anti-1-amino-3-anti-1-amino-3-[18F]-fluorocyclobutane-1-carboxylic acid ([18F]fluciclovine) positron emission tomography/computed tomography (PET/CT) changes reflect response to docetaxel chemotherapy in mCRPC. Results Seven patients with mCRPC were enrolled. Each patient was scheduled to have [18F]fluciclovine PET/CT at baseline, and after 1 and 6 cycles of chemotherapy. Uptake parameters were recorded in the prostate/bed and up to 10 metastatic lesions. Decrease in uptake of ≥30% was considered response (R); appearance of new lesions or >30% increase in uptake was progressive disease (PD); and change of < 30% uptake was stable disease (SD). Prostate specific antigen (PSA) was obtained at baseline and before each cycle. Bone scintigraphy and CT were acquired at baseline and after the 6th cycle. Assessment of response was based on Prostate Cancer Clinical Trial Working Group 3 recommendations. Correlation between [18F]fluciclovine uptake and time to PSA progression was also determined. All patients completed the 1 st and 2 nd [18F]fluciclovine PET/CT, while 4/7 patients completed all 3 scans. PET response correlated with PSA response in 3/7 (42.9%) patients and 3/4 (75%) patients after 1 and 6 cycles of docetaxel, respectively. Bone scan and CT correlated with PSA response in 1/4 (25%) patients. Mean SUVmax and SUVmean were significantly higher in patients with progressive disease versus non-progressive disease after 6 cycles of docetaxel (p<0.05), but not at baseline or after 1 cycle of docetaxel. There was non-significant correlation of changes in [18F]fluciclovine uptake with changes in PSA after 1 and 6 cycles of docetaxel. There was no significant correlation between PET parameters and time to PSA progression. Conclusion [18F]fluciclovine PET/CT has better correlation than CT or bone scan with PSA response for patients with mCRPC treated with docetaxel. [18F]fluciclovine PET/CT did not predict time to PSA progression. Larger studies exploring the utility of [18F]fluciclovine PET for response assessment are recommended.

Response assessment using [ 68 Ga]Ga‐PSMA ligand PET in patients undergoing systemic therapy for metastatic castration‐resistant prostate cancer

The Prostate ◽  
2019 ◽  
Vol 80 (1) ◽  
pp. 74-82 ◽  
Author(s):  
Bernhard Grubmüller ◽  
Sazan Rasul ◽  
Pascal Baltzer ◽  
Harun Fajkovic ◽  
David D'Andrea ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systemic Therapy ◽  
Response Assessment ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Psma Ligand

scholarly journals Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Matthijs C. F. Cysouw ◽  
Gerbrand M. Kramer ◽  
Dennis Heijtel ◽  
Robert C. Schuit ◽  
Michael J. Morris ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Pet Ct

Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT

2016 ◽  
pp. e376-e385
Author(s):  
Ryan C. Lynch ◽  
Ranjana H. Advani
Keyword(s):  
Hodgkin Lymphoma ◽  
Adaptive Design ◽  
Response Assessment ◽  
Early Response ◽  
Clinical Criteria ◽  
Interim Pet ◽  
Early Results ◽  
Pet Ct ◽  
Risk Patients ◽  
Early Response Assessment

Although patients with advanced-stage classic Hodgkin lymphoma have excellent outcomes with contemporary therapy, the outcomes of patients with refractory disease is suboptimal. Identification of these high-risk patients at diagnosis is challenging as the differences in outcomes using clinical criteria are less marked using current modern therapy. Data suggest that an interim PET-CT may be a powerful tool in risk-stratifying patients. Retrospective studies show that a negative interim PET-CT after two to four cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is predictive of favorable outcome independent of IPS score. Currently, there are several ongoing trials that aim to determine whether early-response assessment can be used to select patients who might benefit from modifications of subsequent therapy, either by intensifying or abbreviating regimens and/or omitting radiotherapy with promising early results. Longer follow-up is required to assess whether this strategy impacts overall survival (OS). Herein, we review the results of recent trials using interim PET-CT-based adaptive design in the treatment of advanced HL.

Sign in / Sign up

Export Citation Format

Share Document